BW

Topo IIα (E1102) polyclonal Antibody | BS2643

(No reviews yet) Write a Review
SKU:
BW-BS2643
Availability:
Usually ships in 5 working days
£732.00 - £1,098.00

Description

Topo IIα (E1102) polyclonal Antibody | BS2643 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse

Application: WB IHC

Application Range: WB: 1:500~1:1000 IHC: 1:50~1:200

Background: DNA topoisomerase I and II (Topo I and Topo II) are nuclear enzymes that regulate the topological structure of DNA in eukaryotic cells by transiently breaking and rejoining DNA strands. Eukaryotic topoisomerases are capable of relaxing both positive and negative supercoils, whereas prokaryotic topoisomerases relax only negative supercoils. DNA topoisomerases play a role in DNA replication, recombination and transcription and have been identified as targets of numerous anticancer drugs. Topo I, a ubiquitously expressed, soluble enzyme, acts by introducing a transient break in one strand of DNA, while Topo II acts by making a transient double-strand break. Topo II is encoded by two different genes to generate two distinct isoforms that are designated Topo IIα and Topo IIβ.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: Topo IIα (E1102) polyclonal Antibody detects endogenous levels of Topo Iiα protein.

Molecular Weight: ~ 174 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Topoisomerase II alpha 170 kDa; Topo II alpha; Topoisomerase DNA II alpha 170kDa; TopII alpha; TP2A; TOP2A; TOP2; TOP 2A; EC 5.99.1.3; DNA topoisomerase II alpha isozyme; DNA topoisomerase II 170 kD; DNA topoisomerase 2 alpha; DNA Topoisomerase2

Immunogen: Synthetic peptide, corresponding to amino acids 1071-1220 of Human Topo IIα.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway:

View AllClose